Second sight medical products inc (EYES)
Balance Sheet / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
ASSETS
Current assets:
Cash and cash equivalents

11,327

18,462

25,161

31,682

4,471

4,972

7,476

-

7,839

-

-

-

-

-

-

-

-

-

-

-

-

Cash and cash equivalents

-

-

-

-

-

-

-

5,014

-

639

763

266

539

277

184

0

239

268

407

652

619

Money market funds

-

-

-

-

-

-

-

-

-

12,705

17,366

23,625

10,336

17,546

23,691

-

15,721

-

-

-

34,000

Money market funds

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

-

21,400

26,179

29,086

-

Accounts receivable, net

455

264

629

597

504

1,194

718

475

1,831

668

926

782

274

447

677

0

1,501

1,307

1,208

1,295

708

Inventories, net

1,029

1,264

1,474

1,602

3,250

3,604

3,567

2,812

2,700

3,245

3,052

3,118

3,416

5,810

7,367

9

8,209

8,137

6,805

6,401

5,722

Prepaid expenses and other current assets

299

366

783

1,155

1,395

507

599

809

795

462

702

820

717

603

626

0

1,094

751

1,144

-

927

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

960

-

Total current assets

13,110

20,356

28,047

35,036

9,620

10,277

12,360

9,110

13,165

17,719

22,809

28,611

15,282

24,683

32,545

21

26,764

31,866

35,745

38,396

41,976

Property and equipment, net

1,122

1,125

993

963

1,025

1,114

1,191

1,258

1,299

1,327

1,414

1,466

1,489

1,527

1,525

1

1,432

1,350

1,138

1,001

1,005

Right-of-use assets

2,342

2,399

2,454

2,508

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposits and other assets

25

18

26

41

37

29

66

-39

33

-35

-44

-45

-39

-55

-51

-

-49

-

-

-

-88

Deposits and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

70

57

59

-

Total assets

16,599

23,898

31,520

38,548

10,682

11,420

13,617

10,407

14,497

19,081

24,267

30,122

16,810

26,265

34,121

22

28,245

33,287

36,941

39,456

43,069

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable

1,093

1,126

1,255

1,600

1,305

1,546

1,220

1,611

752

826

558

895

1,156

694

671

0

710

544

330

414

513

Accrued expenses

1,889

2,082

2,562

2,309

2,503

1,975

2,071

2,084

2,425

2,330

2,304

2,246

2,088

1,711

1,766

1

2,068

1,881

1,916

1,611

1,412

Accrued compensation expense

2,698

2,461

2,207

2,080

2,690

2,962

2,448

2,078

2,611

2,266

1,823

1,606

1,600

2,055

1,676

-

2,069

-

-

-

1,362

Accrued compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-

2,249

1,632

-

-

Accrued compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,622

-

Accrued clinical trial expenses

707

734

1,038

1,016

933

934

1,074

941

779

623

632

641

629

555

551

0

616

556

509

486

489

Current operating lease liabilities

237

228

219

210

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract liabilities

335

554

557

218

167

111

260

-

48

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

64

147

369

85

195

263

0

322

783

905

805

600

Contract liabilities

-

-

-

-

-

-

-

162

-

0

0

0

104

456

1,105

1

2,197

2,767

3,545

4,057

4,075

Total current liabilities

6,959

7,185

7,838

7,433

7,598

7,528

7,073

6,876

6,615

6,109

5,464

5,757

5,662

5,666

6,032

6

7,982

8,783

8,840

8,997

8,451

Long term operating lease liabilities

2,365

2,427

2,487

2,586

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total liabilities

9,324

9,612

10,325

10,019

7,598

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Commitments and contingencies

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

-

0

0

0

0

Stockholders’ equity:
Preferred stock, no par value, 10,000 shares authorized; none outstanding

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 15,643 and 9,542 at December 31, 2019 and December 31, 2018, respectively

264,008

263,656

263,656

263,418

229,019

221,774

216,805

206,163

202,156

200,867

200,867

200,416

186,769

186,618

186,618

166

166,049

165,641

165,470

163,441

163,171

Common stock issuable

-

-

-

-

-

0

0

-

153

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issuable

-

-

-

-

-

-

-

218

-

86

21

218

153

87

22

-

205

-

-

-

166

Common stock to be issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

114

28

-

-

Common stock to be issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

237

-

Additional paid-in capital

48,613

48,131

47,445

46,586

44,111

43,311

42,434

41,807

40,522

39,559

38,654

37,719

30,697

29,911

29,012

28

27,277

26,507

25,651

25,087

24,590

Notes receivable to finance stock option exercises

-

-

-

-

-

-

-

-

-

0

-1

-1

-2

-2

-3

-

-5

-

-

-153

-171

Notes receivable to finance stock option exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

5

30

-

-

Accumulated other comprehensive loss

-562

-585

-574

-583

-575

-580

-604

-527

-572

-572

-486

-578

-608

-524

-558

-0

-581

-546

-476

-533

-474

Accumulated deficit

-304,784

-296,916

-289,332

-280,892

-269,471

-260,613

-252,091

-244,130

-234,377

-226,968

-220,252

-213,409

-205,861

-195,491

-187,002

-178

-172,682

-167,208

-162,542

-157,620

-152,664

Total stockholders' equity

-

-

-

-

-

-

-

3,531

-

12,972

18,803

24,365

11,148

20,599

28,089

-

20,263

-

-

-

34,618

Total stockholders’ equity

7,275

14,286

21,195

28,529

3,084

3,892

6,544

-

7,882

-

-

-

-

-

-

15

-

24,504

28,100

30,459

-

Total liabilities and stockholders’ equity

16,599

23,898

31,520

38,548

10,682

11,420

13,617

10,407

14,497

19,081

24,267

30,122

16,810

26,265

34,121

22

28,245

33,287

36,941

39,456

43,069